Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
1. A compound of the formula:
2. A pharmaceutical composition comprising an effective amount in a pharmaceutically acceptable carrier of the compound of claim 1 , in a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , in an oral dosage form.
4. The pharmaceutical composition of claim 3 , wherein the oral dosage form is a solid dosage form.
5. The pharmaceutical composition of claim 4 , wherein the solid dosage form is a tablet.
6. The pharmaceutical composition of claim 4 , wherein the solid dosage form is a capsule.
7. The pharmaceutical composition of claim 3 , wherein the oral dosage form is a liquid dosage form.
8. The pharmaceutical composition of claim 7 , wherein the liquid dosage form is a suspension or solution.
9. The pharmaceutical composition of claim 2 , in an intravenous formulation.
10. The pharmaceutical composition of claim 2 , in a parenteral formulation.
11. A compound of the formula:
12. A solid dosage form comprising an effective therapeutic amount in a pharmaceutically acceptable carrier of a compound of the formula:
13. A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula
in a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , in a solid dosage form that delivers at least 300 mg of the compound.
15. The pharmaceutical composition of claim 13 , in a solid dosage form that delivers at least 400 mg of the compound.
16. The pharmaceutical composition of claim 13 , in a solid dosage form that delivers at least 500 mg of the compound.
17. The pharmaceutical composition of claim 13 , in a solid dosage form that delivers at least 600 mg of the compound.
18. The pharmaceutical composition of claim 13 , in a solid dosage form that delivers at least 700 mg of the compound.
19. The pharmaceutical composition of claim 13 , wherein the pharmaceutically acceptable carrier is suitable for oral delivery.
20. The pharmaceutical composition of claim 19 , wherein the pharmaceutically acceptable carrier is in the form of a tablet.
21. The pharmaceutical composition of claim 19 , wherein the pharmaceutically acceptable carrier is in the form of a capsule.
22. The pharmaceutical composition of claim 13 , in an intravenous formulation.
23. The pharmaceutical composition of claim 13 , in a parenteral formulation.
24. The pharmaceutical composition of claim 19 , wherein the pharmaceutically acceptable carrier is in the form of a suspension or solution.
25. A compound of the formula
wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
26. The compound of claim 25 , wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
27. A solid dosage form comprising an effective amount in a pharmaceutically acceptable carrier of a compound of the formula
wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
28. The solid dosage form of claim 27 , wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
29. A pharmaceutical composition comprising an effective therapeutic amount in a pharmaceutically acceptable carrier of a compound of the formula
wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
30. The pharmaceutical composition of claim 29 , wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
31. The pharmaceutical composition of claim 13 , that delivers at least 400 mg of the compound.
32. The pharmaceutical composition of claim 13 , that delivers at least 500 mg of the compound.
33. The pharmaceutical composition of claim 13 , that delivers at least 600 mg of the compound.
34. The pharmaceutical composition of claim 13 , that delivers at least 700 mg of the compound.